ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jul 29, 2013
AbbVie’s Humira Continues to Drive Strong Performance; Pipeline Advances
Humira continues to drive strong performance in the second quarter, while AbbVie's pipeline advances.
Jul 18, 2013
Abbott's Nutrition Business Leads the Charge in Its Second Quarter
Abbott continues to be an international growth story. Let's dig into the firm's second-quarter numbers.
Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015.
Dec 18, 2012
Inside the New Abbott: A Lot Like the Old Abbott But Without Humira
We take a dive inside the prospects of the “new” Abbott, which is quite a bit like the old Abbott—minus Humira.
Dec 11, 2012
Inside AbbVie: A Look at a New Pharmaceutical Giant
Let's take a look at Abbott's new standalone business, AbbVie.
Jul 18, 2012
Abbott’s Results Are Solid In Spite of Currency Headwinds
Global pharmaceutical firm Abbott reported strong second-quarter results Wednesday. We think the shares are fairly valued.
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry.
Oct 20, 2011
Abbott Reports Decent Third Quarter; Decides to Break Itself Into Two
Abbott posted decent revenue and earnings expansion in its third quarter and surprised investors with a decision to split the company into two distinct publicly-traded entities. We like the move and think the firm remains undervalued.
Aug 1, 2011
Abbott's Shares Look Cheap
We dive into Abbott's valuation.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.